Frequently Asked Questions
The market is segmented based on , By Drug Class (Corticosteroids, Disease-Modifying Anti-Rheumatic Drugs (DMARDS), Nonsteroidal Anti-Inflammatory Drugs (NSAIDS), Others), Route of Administration (Oral, Parenteral, Others), End-Users (Hospitals, Homecare, Specialty Clinics, Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, online Pharmacies and Others) – Industry Trends and Forecast to 2029.
.
The Global Polymyalgia Rheumatica Treatment Market size was valued at USD 180.00 USD Million in 2021.
The Global Polymyalgia Rheumatica Treatment Market is projected to grow at a CAGR of 14% during the forecast period of 2022 to 2029.
The major players operating in the market include F. Hoffmann La Roche , Mylan N.V., Teva Pharmaceutical Industries , Sanofi, Pfizer , GSK plc, Novartis AG, AstraZeneca, Johnson & Johnson Private Limited, Sun Pharmaceutical Industries , Merck & Co. , Lilly, Amgen , PuraCap Pharmaceutical LLC, Glenmark Pharmaceuticals Limited..
The market report covers data from the U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
